AP
GALT icon

Atwood & Palmer’s Galectin Therapeutics GALT Stock Holding History

Atwood & Palmer’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$46.4K Hold
10,000
– – ﹤0.01% 254
2026
Q1 		$27.9K Hold
10,000
– – ﹤0.01% 297
2025
Q4 		$41.6K Hold
10,000
– – ﹤0.01% 251
2025
Q3 		$42.4K Buy
+10,000
New +$37.6K ﹤0.01% 257

Other funds holding GALT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
GWM
Geneos Wealth Management Englewood, Colorado $4.9B AUM 23.65% 1-Year Est. Return
RGF
Retirement Guys Formula Maumee, Ohio $266M AUM 25.32% 1-Year Est. Return
SA
Sovran Advisors San Diego, California $1.34B AUM 21.63% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Atwood & Palmer's GALT Position: Q2 2026 in Review

Atwood & Palmer held its Galectin Therapeutics (GALT) position steady in Q2 2026 at 10,000 shares worth $46.4K. The position accounts for ﹤0.01% of the portfolio, ranked #254.

Atwood & Palmer first reported a position in GALT in Q3 2025 and has held it in 4 quarters since. 37 funds tracked by Wall St. Rank hold GALT as of Q2 2026.

  • Atwood & Palmer held 10,000 shares of Galectin Therapeutics worth $46.4K as of Q2 2026.
  • Atwood & Palmer left its Galectin Therapeutics share count unchanged in Q2 2026.
  • Galectin Therapeutics made up ﹤0.01% of Atwood & Palmer's portfolio in Q2 2026, its #254 holding.
  • Atwood & Palmer first reported a position in Galectin Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 37 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2026.

Based on Atwood & Palmer's 13F filing for Q2 2026, filed 8 Jul 2026.